Radical resection of advanced gallbladder cancer after gemcitabine combined with S-1 and Sintilimab chemotherapy: A case report

This case illustrates that combining neoadjuvant therapy with immune checkpoint inhibitors is a crucial approach for enhancing the prognosis of patients with advanced GBC. This strategy increases the likelihood of achieving radical surgical resection by facilitating downstaging treatment, which could enable conversion surgery for patients initially classified as inoperable. In addition, this case successfully demonstrates that sintilimab is a viable, effective, and economically advantageous option for the treatment of advanced GBC transformation.